HomeCompareBXRBF vs JNJ

BXRBF vs JNJ: Dividend Comparison 2026

BXRBF yields 5.91% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXRBF wins by $15.7K in total portfolio value
10 years
BXRBF
BXRBF
● Live price
5.91%
Share price
$7.25
Annual div
$0.43
5Y div CAGR
14.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.0K
Annual income
$4,910.33
Full BXRBF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BXRBF vs JNJ

📍 BXRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXRBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXRBF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXRBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXRBF
Annual income on $10K today (after 15% tax)
$502.45/yr
After 10yr DRIP, annual income (after tax)
$4,173.78/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BXRBF beats the other by $187.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXRBF + JNJ for your $10,000?

BXRBF: 50%JNJ: 50%
100% JNJ50/50100% BXRBF
Portfolio after 10yr
$38.1K
Annual income
$4,799.86/yr
Blended yield
12.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BXRBF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$11.32
+56.1% upside vs current
Range: $11.32 — $11.32
Altman Z
-0.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXRBF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXRBFJNJ
Forward yield5.91%2.13%
Annual dividend / share$0.43$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR14.8%28%
Portfolio after 10y$46.0K$30.3K
Annual income after 10y$4,910.33$4,689.40
Total dividends collected$21.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$11.32$228.73

Year-by-year: BXRBF vs JNJ ($10,000, DRIP)

YearBXRBF PortfolioBXRBF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,379$678.60$10,592$272.30+$787.00BXRBF
2$13,004$828.44$11,289$357.73+$1.7KBXRBF
3$14,930$1,015.77$12,123$472.89+$2.8KBXRBF
4$17,226$1,251.23$13,141$629.86+$4.1KBXRBF
5$19,981$1,548.92$14,408$846.81+$5.6KBXRBF
6$23,307$1,927.59$16,021$1,151.60+$7.3KBXRBF
7$27,351$2,412.39$18,122$1,588.22+$9.2KBXRBF
8$32,303$3,037.32$20,930$2,228.20+$11.4KBXRBF
9$38,412$3,848.73$24,792$3,191.91+$13.6KBXRBF
10$46,012$4,910.33$30,274$4,689.40+$15.7KBXRBF

BXRBF vs JNJ: Complete Analysis 2026

BXRBFStock

Bendigo and Adelaide Bank Limited provides banking and financial products and services to retail customers and small to medium sized businesses in Australia. The company operates through Consumer, Business and Agribusiness, and Corporate segments. It offers a range of products and services, including personal and business banking, financial planning, commercial mortgages and unsecured loans, investment products, insurance, and superannuation. The company also provides retail banking products and services; home loans for the mortgage broker and mortgage manager market; rural bank products and services; wealth management services; investments and funds management services, commercial loans, access to funeral bonds, estates and trusts management services, and corporate trustee and custodial services; and banking products and services to agribusiness participants. It operates 139 Bendigo Bank, 314 Community Bank, 13 Delphi Bank, 16 Alliance Bank, and 4 private franchise branches, as well as 191 rural bank points. The company was founded in 1858 and is headquartered in Bendigo, Australia.

Full BXRBF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BXRBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXRBF vs SCHDBXRBF vs JEPIBXRBF vs OBXRBF vs KOBXRBF vs MAINBXRBF vs ABBVBXRBF vs MRKBXRBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.